The DOI matches its Crossref record; 59 of the 62 references it cites were found in a registry or an index.
Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials
Abstract
Atrial fibrillation (AF) is a major public health concern with a rising prevalence. Although sodium–glucose cotransporter 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) have shown the respective favorable effects on reducing the occurrence of AF/atrial flutter (AFL), comparative protective AF/AFL effects between above 2 novel antidiabetic agents remain unavailable. Thus, we aimed to evaluate the comparative efficacy of SGLT2is and GLP-1RAs in reducing the risk of AF/AFL in patients with type 2 diabetes and estimate relative rankings of interventions. PubMed, Embase, and ClinicalTrials.gov were searched up to December 1, 2020. All available randomized controlled trials comparing SGLT2is and GLP-1RAs with one another or placebo in patients with type 2 diabetes were included. Pooled results were shown as risk ratios (RRs) with 95% confidence intervals (CIs). We used a frequentist network meta-analysis to evaluate the outcomes of interests. Thirty-six randomized controlled trials including 85,701 participants with type 2 diabetes were identified. Compared with placebo, both SGLT2is (RR: 0.82, 95% CI, 0.68–0.99) and GLP-1RAs (RR: 0.86, 95% CI, 0.76–0.97; RR long-acting ones: 0.87, 95% CI, 0.76–0.99; RR short-acting ones: 0.72, 95% CI, 0.45–1.14) significantly reduced AF/AFL risk. No significant difference between SGLT2is and GLP-1RAs was noted (RR: 0.95, 95% CI, 0.76–1.2). Compared with placebo, results from the analysis showed an RR of 0.72 (95% CI, 0.45–1.14) for short-acting GLP-1RAs and 0.87 (95% CI, 0.76–0.99) for long-acting GLP-1RAs in reducing the risk of AF/AFL. Compared with placebo, both SGLT2is and GLP-1RAs possessed favorable effects on reducing the risk of AF/AFL. However, no difference was observed when comparisons were made between them. In addition, long-acting ones may confer a more pronounced AF/AFL reduction benefit compared with placebo.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1RAs have been found to significantly reduce AF risk in patients with diabetes compared with placebo [30] and other glucose-lowering agents including metformin, sulfonylureas, and insulin [31].”
From Protection against stroke with glucagon-like peptide-1 receptor agonists: a comprehensive review of potential mechanisms (2022) · cites this paper as [30]
Citations
Cites
Hutton, B., Salanti, G., Caldwell, D. M., Chaimani, A., Schmid, C. H., Cameron, C., Ioannidis, J. P. A., Straus, S., Thorlund, K., Jansen, J. P., et al. (2015) · Annals of Internal Medicine · doi:10.7326/m14-2385 · Cited by 8,269
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629 · cited 2×
“5/1 Matching placebo 109 1648 (635/1013) 1649 (660/989) 3297 (39) C”
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Perkovic, V., Jardine, M. J., Neal, B., Bompoint, S., Heerspink, H. J. L., Charytan, D. M., Edwards, R., Agarwal, R., Bakris, G., Bull, S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811744 · Cited by 6,189
Salanti, G., Ades, A. E., & Ioannidis, J. P. A. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.03.016 · Cited by 3,766
Davies, M. J., D’Alessio, D. A., Fradkin, J., Kernan, W. N., Mathieu, C., Mingrone, G., Rossing, P., Tsapas, A., Wexler, D. J., & Buse, J. B. (2018) · Diabetes Care · doi:10.2337/dci18-0033 · Cited by 3,518 · cited 1×
“) extracted data from the included studies as follows: (1) the author surname, year of publication, and study design; (2) patient characteristics and follow-up durations; (3) interventions; and (4) outcomes of interest.”
MethodGerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163 · cited 1×
“Husain et al, 2019 NCT02692716 14 Matching placebo 190 1591 (507/1084) 1592 (500/1092) 3183 (32) C”
Graphical tools for network meta-analysis in STATA
Chaimani, A., Higgins, J. P. T., Mavridis, D., Spyridonos, P., & Salanti, G. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076654 · Cited by 2,473
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409 · cited 2×
“Barnett et al, 2014 NCT01164501 Empagliflozin (10/25 mg) matching placebo Matching placebo 52 419 (170/249) 319 (138/181) 738 (42) C”
Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Husain, M., Birkenfeld, A. L., Donsmark, M., Dungan, K., Eliaschewitz, F. G., Franco, D. R., Jeppesen, O. K., Lingvay, I., Mosenzon, O., Pedersen, S. D., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901118 · Cited by 1,997 · cited 1×
“8 Matching placebo 198 4668 (1657/3011) 4672 (1680/2992) 9340 (36) C”
Cited by
Epidemiology and modifiable risk factors for atrial fibrillation
Elliott, A. D., Middeldorp, M. E., Van Gelder, I. C., Albert, C. M., & Sanders, P. (2023) · Nature Reviews Cardiology · doi:10.1038/s41569-022-00820-8 · Cited by 368
Vergès, B., Aboyans, V., Angoulvant, D., Boutouyrie, P., Cariou, B., Hyafil, F., Mohammedi, K., & Amarenco, P. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01686-3 · Cited by 72
SGLT2 inhibition, circulating metabolites, and atrial fibrillation: a Mendelian randomization study
Li, J., Yu, Y., Sun, Y., Yu, B., Tan, X. W., Wang, B., Lu, Y., & Wang, N. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02019-8 · Cited by 73
“[43] Meta-analyses implied either no effect [8, 44] or possible protective effects [9, 45–49] of SGLT2 against AF.”
BackgroundZhang, H., Ding, L., Mi, L., Zhang, A.-K., Zhang, K., Jiang, Z., Yu, F., Yan, X.-X., Shen, Y.-J., & Tang, M. (2023) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwad356 · Cited by 58
Chan, Y., Chao, T., Chen, S., Lee, H., Li, P., Chen, W.-M., Yeh, Y., Kuo, C.-T., See, L., & Lip, G. Y. H. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01549-x · Cited by 49
“Conversely, some meta-analyses indicated that GLP-1RA was associated with a lower risk of AF/AFL compared to other glucose-lowering agents in patients with type 2 diabetes [24, 26].”
Result
Metadata
- Authors
- Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B.
- Affiliations
- First Affiliated Hospital of Guangzhou Medical University (CN)
- Corresponding author
- Li, Wenjie
- Venue
- Journal of Cardiovascular Pharmacology
- Published
- 2022-03
- Volume
- 79
- Issue
- 3
- Pages
- 281-288
- ISSN
- 0160-2446 (ISSN-L)
- OpenAlex
- W4200064002
- Cited by
- 35
- References
- 62
- Citations by year
- 2026: 6 · 2025: 6 · 2024: 7 · 2023: 9 · 2022: 7
- FWCI
- 1.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Cardiovascular Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Atrial Fibrillation Management and Outcomes
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Keywords
- SGLT2 inhibitors, GLP-1 receptor agonists, atrial fibrillation, atrial flutter, type 2 diabetes, antidiabetic drugs, drug efficacy comparison, risk mitigation, network meta-analysis ranking
- MeSH terms
- Glucagon-Like Peptide Receptors, Network Meta-Analysis as Topic, Network Meta-Analysis, Sodium-Glucose Transporter 2 Inhibitors, Atrial Fibrillation, Atrial Flutter, Diabetes Mellitus, Type 2, Glucose, Humans, Hypoglycemic Agents, Sodium, Randomized Controlled Trials as Topic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials. https://app.cochat.ai/papers/10.1097/fjc.0000000000001197
- The paper
- Li, W., Chen, X., Xie, X., Xu, M., Xu, L., Liu, P., & Luo, B. (2022). Comparison of Sodium–Glucose Cotransporter 2 Inhibitors and Glucagon-like Peptide Receptor Agonists for Atrial Fibrillation in Type 2 Diabetes Mellitus: Systematic Review With Network Meta-analysis of Randomized Controlled Trials. Journal of Cardiovascular Pharmacology. https://doi.org/10.1097/fjc.0000000000001197
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.